Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-01-70
Phase 3
Completed
- Conditions
- Ocular HypertensionOpen-Angle Glaucoma
- Registration Number
- NCT00047541
- Lead Sponsor
- Alcon Research
- Brief Summary
To compare intraocular pressure lowering effectiveness of a combination drug vs. two individual drugs dosed alone.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie combination IOP therapy in open-angle glaucoma and ocular hypertension as studied in NCT00047541?
How does combination IOP therapy in NCT00047541 compare to standard-of-care monotherapies in terms of efficacy and safety profiles?
What biomarkers are associated with response to combination IOP-lowering treatments in patients with open-angle glaucoma or ocular hypertension?
What are the potential adverse events of combination IOP therapy in NCT00047541 and how are they managed in clinical practice?
What related compounds or combination approaches have been developed by Alcon Research for treating open-angle glaucoma and ocular hypertension beyond NCT00047541?
Trial Locations
- Locations (1)
Clinical Trial Sites
🇺🇸Fort Worth, Texas, United States
Clinical Trial Sites🇺🇸Fort Worth, Texas, United States